Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Poised to Capitalize on China’s Consumer-Driven Growth

It is estimated that China will experience almost $2 trillion in new consumer-driven consumption by 2021, and Chinese consumers are about twice as likely to use a mobile device to make retail purchases as consumers in Europe and the United States. Right in line to capitalize on this, Moxian, Inc. (NASDAQ: MOXC) has recently upgraded its mobile payments capability as it continues bridging the gap between e-commerce and brick-and-mortar retail, helping move Chinese consumers from online views to in-store purchases at the physical locations of Moxian’s clients. An article discussing this reads: “The company’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeping them engaged and referring new customers. The company’s ingenious and captivating online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business with the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses with the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant clients the ability to study consumer behavior and custom-tailor offerings to consumers.”

To view the full article, visit http://dtn.fm/f1lhG

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Moxian Inc. MOXC | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Enters Collaboration Agreement with Phasex Corporation

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the worldwide life sciences industry, this morning announced a collaboration with Phasex Corporation, one of the world’s most experienced supercritical fluid (“SCF”)-based toll processors. The goal of the collaboration is to combine PBI’s recently patented Ultra Shear Technology with Phasex’s SCF-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. “Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies,” Richard T. Schumacher, president and CEO of PBI, stated in the news release. “Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration.”

To view the full press release, visit http://dtn.fm/7IiPk

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of our patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively prepared using existing technologies.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Approaching Commercialization of IGC-AD1 in Early 2018

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, the expression of GSK3β is reduced by as much as 62 percent. “Based on this and other previously announced compelling data, we are readying IGC-AD1, brand name Hyalolex, in a liquid formulation for commercialization in early 2018,” Ram Mukunda, CEO of IGC, stated in the news release. “We have identified Germany, Canada and certain licensed medical cannabis states in the U.S. for commercialization… Our initial research indicates that there are about 7.8 million patients with AD in these combined markets.” The newly-announced results, when combined with earlier reported data showing that IGC-AD1 reduces Aβ production and inhibits Aβ aggregation without any neuronal toxicity, represent a novel breakthrough toward the treatment of Alzheimer’s, which is known as America’s most expensive disease with an estimated annual cost to the U.S. economy of $236 billion.

To view the full press release, visit http://dtn.fm/vc40E

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC, MissionIRNewsBreaks | Leave a comment

Pressure BioSciences Inc. (PBIO) is “One to Watch”

  • Poised to disrupt sciences sample preparation market estimated at $6 billion
  • Nearly 300 patented enabling technology platform products installed at more than 150 sites worldwide
  • Two patents awarded in China for Ultra Shear Technology used in wide range of industrial applications, including “clean foods”
  • Finalist in prestigious 2017 R&D 100 Awards recognizing top revolutionary technologies
  • Technology being used as part of the U.S. “Cancer Moonshot” initiative

Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

For more information, visit the company’s website at www.PressureBioSciences.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Pressure BioSciences Inc. PBIO | Leave a comment

Nevada Gold & Casinos, Inc. (NYSE: UWN) Improving Casino Odds

  • Largest mini-casino operator in Washington
  • Increasing revenues and profits
  • Better odds than betting in a casino

Americans love casino gambling. In near record numbers, over 81 million people visited U.S. casinos in the 12-month period ended in the spring of 2017 (http://dtn.fm/jFUn2). From nickel slots to blackjack, almost everyone placed some form of wager, even though the house always has the edge. With such a penchant for casino gambling, the U.S. gaming industry is poised for another year of growth.

Blackjack has the best odds of winning, with a house edge of one to two percent in most casinos, notwithstanding the casino’s built-in advantage between the promised payout and the inherent odds of the game. The house never takes the extra risk; the bettor does. Popular slot machines have the lowest odds of winning, with a house edge of 10 percent or more. Despite the thrill and excitement, walking away a winner at a casino is a long shot. Rather than betting “in” casinos, better odds can be found betting “on” casinos. Well-run casinos are money pumps, and a more likely winning bet is buying a gaming company’s stock at the biggest casino of them all, the stock market.

Each year, gaming revenues in the U.S. yield more profits than the movie and recorded music industries combined. Even the combined revenue of the four major U.S. professional sports leagues is dwarfed by earnings from the commercial casinos industry. Casino stocks have surged this year with the big names leading the way. A smarter bet may be to look at smaller casino operators that enjoy similar ratios but haven’t made big moves yet.

Las Vegas-based Nevada Gold & Casinos, Inc. (NYSE MKT: UWN) is just such an operator. Nevada Gold & Casinos finances, develops, owns and operates gaming properties and projects in multiple U.S. locations. The company’s Washington Gold is the largest operator of mini-casinos in Washington. Nevada Gold also owns a slot route operation in Deadwood, South Dakota, and the Club Fortune Casino in Henderson, Nevada, with 540 slot machines, seven table games, a poker room, two bars, an entertainment lounge and a sports book. Washington’s mini-casinos have limited game options based on state law, but most offer multiple card games. Combined, Nevada Gold’s Washington facilities have over 120 table games including Blackjack, Pai Gow Poker, Baccarat, Spanish 21, Blackjack – Double Action, Ultimate Holdem, and Three and Four Card Poker. Additional banked table games are permitted along with poker and pull tabs. The company’s 24-hour Washington Gold casinos include full service restaurants with bars and collectively employ 1,100 people.

In July, Nevada Gold & Casinos announced financial results for the fourth quarter and year ended April 30, 2017 (http://dtn.fm/T63qV). For the fourth quarter of fiscal 2017, the company reported net revenues of $19.8 million and net income of $1.2 million, or $0.07 per share. For the fiscal year 2017, the company reported net revenues of $74.6 million, compared to $70.2 million in fiscal year 2016. The Board of Directors authorized a share repurchase program of $2.0 million in 2016 and completed the buy back at favorable prices. The Board has also approved an additional $2.0 million share buyback, a strong indication that the company believes it’s undervalued in the market.

Since the stock market’s recovery began in 2009, major gambling companies in the U.S. have beaten the broader market several fold. Expanding profit potential has triggered a rush within the gaming industry as companies buy up other players to capture as much market share as possible. This could bode well for Nevada Gold as a potentially attractive target. As a well-run profitable gaming company, Nevada Gold may also provide outsized returns of its own and deliver much better odds to pocket casino cash.

For more information, visit the company’s website at www.NevadaGold.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Small Cap News | Leave a comment

MissionIRNewsBreaks – India Globalization Capital (NYSE: IGC) Achieves Breakthrough with Potential to Prevent, Combat Alzheimer’s

India Globalization Capital (NYSE MKT: IGC), a first mover in the cannabis-based combination therapy space, recently announced that it is readying a line of cannabis-based medical dispensary products that target Alzheimer’s disease (http://dtn.fm/tQo00). IGC is engineering genetic cell lines which demonstrate that, at various concentrations of tetrahydrocannabinol (THC), the protein Aβ decreases as much as 40 percent without neuron damage. An article discussing this reads: “This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.”

To view the full article, visit http://dtn.fm/8w3OJ

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC, MissionIRNewsBreaks | Leave a comment

Moxian, Inc. (NASDAQ: MOXC) Positioned to Exploit China’s Consumer Consumption Growth

  • China will see nearly $2 trillion in new consumer-driven consumption by 2021
  • Moxian facilitates Chinese consumer consumption
  • Tweaked business model positions Moxian for more rapid expansion

China’s overall economic growth has slowed from its nearly 30 years of 10 percent annual improvement, but the Chinese consumer economy is still massive in absolute terms and poised for steadily increased expansion. With a population of 1.3 billion, China now comprises the world’s second-largest economy. Since the market reforms in 1978, China has shifted from a central government planned economy to a market-based economy and has experienced rapid consumer-driven economic development. China is now an upper middle-income country that sustains a targeted 6.5 percent GDP growth rate and has lifted nearly a billion people out of poverty. From centrally planned to consumer-driven, China’s growth is now consumer reliant.

China will see nearly $2 trillion in new consumer-driven consumption by 2021, which equates to about 27 percent of “total consumption growth” that will occur in the world’s major economies during the same period (http://dtn.fm/p4EEb). Over the next several years, China will prove to be one of the greatest opportunities in the world for consumer-oriented companies.

Technology is stoking China’s consumer growth. Skipping historic hard wired infrastructure, the Chinese consumer is mobile and internet savvy. About twice the percentage of Chinese consumers are likely to use a mobile device to make retail purchases as their counterparts in Europe and the United States.

Recently upgrading its mobile payments capability, Moxian, Inc. (NASDAQ: MOXC) is bridging e-commerce to brick and mortar retail. Moxian’s creative and socially interactive online platforms and mobile applications are moving the Chinese consumer from online views to retail purchases at Moxian’s brick and mortar client locations. The company’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeping them engaged and referring new customers.

The company’s ingenious and captivating online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business with the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses with the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant client the ability to study consumer behavior and custom-tailor offerings to consumers.

To exploit the immense upside trend, Moxian recently tweaked its business model to grow even more rapidly by utilizing a joint venture strategy and leveraging entrenched businesses to efficiently penetrate China’s top four markets. MOXC’s relationship with China’s dominant payment processor, UnionPay, is integral to the new strategy. A UnionPay processing module on the Moxian+ platform allows MOXC to attract new joint venture partners in China and neighboring Asian markets. The Moxian+ Merchant platform now offers digital processing modules for UnionPay, Alipay, and WeChatPay. These modules allow payment processing as Moxian drives evermore traffic and engages evermore consumers. These changes place Moxian even more in the mix and poised to reap substantial rewards by facilitating the immense growth of the Chinese consumer market.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Moxian Inc. MOXC | Leave a comment

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) Expands Lithium Mining Project

  • STLHF adds 6,000 more acres to its Bristol Dry Lake Lithium Project, and aims to be a significant low-cost, domestic producer of battery-grade lithium materials
  • Electric cars and smart phones use ion-lithium rechargeable batteries — driving prices and demand. According to Platt’s, lithium production can be expected to grow to 500,000 metric tons by 2020 from 200,000 today
  • Goldman Sachs terms lithium “the new gasoline” as it projects that electric cars will have 61% market penetration by 2040, when it sees sales of electric cars outnumbering gasoline units

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is part of a worldwide race to produce enough lithium to satisfy the growing demand for the ore from electric car makers and smart phone makers. The question now is how soon miners can bring their lithium supply online to meet that demand. Companies such as Tesla have an insatiable demand for lithium, with Platt’s projecting that production could grow to 500,000 metric tons by 2020 from 200,000 today (http://dtn.fm/0wIWS).

STLHF is a junior lithium mining company with a market cap of only $62 million. Along with others, it is aggressively seeking to fill increased worldwide demand for lithium for the manufacture of lithium-ion batteries used in the manufacture of electric cars and smart phones. Goldman Sachs has termed lithium as “the new gasoline”, according to an article titled, “The Global Scramble For Lithium” (http://dtn.fm/Ze2yY). STLHF is focused on finding more lithium in the Bristol Dry Lake project to boost its valuation for investors as a significant low-cost, domestic producer of battery-grade lithium materials.

While Australia, Chile and China are top producers of lithium globally, according to Lithium Investing News (http://dtn.fm/5M5lO), STLHF has announced that its subsidiary, California Lithium Ltd., has signed an amendment agreement with National Chloride Company of America to expand its land production lease in California (http://dtn.fm/4SujJ). The U.S. is only the eighth-ranked lithium producer worldwide. According to the U.S. Geological Survey, “The U.S. has a lot more untapped lithium resources than economically mined reserves at this point” (Feb, 2017). Standard Lithium believes significant opportunity exists to develop geopolitically secure domestic U.S. lithium assets. The amended agreement adds 6,000 acres to STLHF’s land holdings in the Bristol Dry Lake Lithium Project, now totaling 25,000 acres in the Mojave region of San Bernardino County in California.

Lithium Investing News reports that lithium production rose 12% in 2016 to 35,000 metric tons. Morgan Stanley projects that more electric cars will be sold by 2040 than gas-powered cars, with market penetration growing from 16% in 2030 to 51% by 2040 (http://dtn.fm/w9RyQ). In its most bullish scenario, projections are that electric cars will reach 60% market penetration by 2040 and 90% by 2045. Whichever projection comes true, 159,000 more electric vehicles were on the road in 2016, and sales were up 38% over 2015 levels, according to research from FleetCarma (http://dtn.fm/aFHJ8).

For more information, visit the company’s website at www.StandardLithium.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Standard Lithium Ltd. STLHF | Leave a comment

MissionIRNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Sharpens Focus on Potentially Game-Changing Sustained Release Cannabinoid Formulation

Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) recently entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release cannabinoid formulation. The agreement grants Emblem the exclusive right to Canntab’s patents and expertise in Canada to develop, commercialize, use, sell and offer—but not import or export—the product, which will be sold under the Emblem brand. An article discussing this reads: “For pharmaceutical ingredients that are typically short-acting, like cannabinoids, sustained release formulations enable dosage schedules that are more convenient, offer longer action duration and are better accepted by health care professionals and patients. The patent-pending extended release formulation being collaboratively developed by Emblem and Canntab will enable medical professionals, for the first time, to establish proper dosages for patients and will, for the patients, make it easier to take medical cannabis. Emblem believes the development of advanced dosage forms, and the pharmacokinetic and clinical research associated with this development, will effectively advance cannabinoid therapy. The company also anticipates that introducing sustained release cannabinoid formulations that are easily titratable will significantly increase the market for cannabinoid-based medications—especially for the treatment of conditions like chronic neuropathic pain.”

To view the full article, visit http://dtn.fm/9k9NF

About Emblem

Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. For more information, visit the company’s website at www.emblemcorp.com

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Emblem Corp. EMMBF, MissionIRNewsBreaks | Leave a comment

India Globalization Capital (NYSE: IGC) Announces Significant Breakthrough that Could Potentially Prevent, Fight Alzheimer’s Disease

  • Seeks patent on new therapy for drug that employs concentrations of THC
  • Data for drug candidate IGC-AD1 finds that it reduces buildup of ‘senior plaque’ without causing death of neurons, which can lead to memory loss
  • IGC plans to commercialize drug as a supplement to be marketed as a medical dispensary product

India Globalization Capital (NYSE MKT: IGC) recently announced that it is assembling a line of cannabis-based medical dispensary products targeting Alzheimer’s disease (http://dtn.fm/Rcl69). The company is engineering genetic cell lines which show that, at various concentrations of THC, the protein Aβ decreases as much as 40% without neuron damage.

This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.

IGC is a first-mover in the cannabis-based combination therapy space. The Bethesda, Maryland-based company has already filed for six patents in the markets of epilepsy, eating disorders and pain. It is also working on additional filings for indications including depression, Alzheimer’s disease, post-traumatic stress disorder and Parkinson’s disease.

“As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss,” IGC CEO Ram Mukunda stated in a news release. “These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50% and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease.”

It is believed that a primary cause of Alzheimer’s disease is the buildup of senile plaque, or Aβ plaque, in the cerebral cortex and hippocampus. As the disease progresses, Aβ oligomers directly cause synaptic dysfunction and the death of neurons, leading to memory loss.

“In vitro, our product demonstrates these critical factors and we are pursuing a patent filing that protects this therapy,” Mukunda added.

IGC has a two-step plan. First, it will position IGC-AD1 both as a treatment and a preventative therapy for Alzheimer’s. Second, IGC plans to commercialize a supplement version of the drug to be sold as a medical dispensary product.

Alzheimer’s affects more than 5.3 million Americans, and more than 65% of the patients suffering from the disease are women. It is known as America’s most expensive disease, costing the economy an estimated $236 billion. Over the next 20 years, the number of people with the disease is expected to double. Alzheimer’s begins 20-25 years prior to clear symptoms. To date, no effective cure has been found.

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC | Leave a comment